



# Cardiac dysfunction evoked by ECG and echocardiography changes and release of cardiac biomarkers in patients with aneurysmal subarachnoid haemorrhage. Case presentation and literature review

Raluca Ungureanu<sup>1</sup>, Mihai Dumitru<sup>2</sup>,  
Gabriel Iacob<sup>3</sup>

<sup>1</sup> Anaesthesia and Intensive Care Department, Coltea Clinical Hospital, Bucharest, ROMANIA

<sup>2</sup> Anatomy Department, Carol Davila University of Medicine and Pharmacy, Bucharest, ROMANIA

<sup>3</sup> Neurosurgery Department, Emergency University Hospital, Bucharest, ROMANIA

## ABSTRACT

The invisible brain-heart link has been observed and described for centuries now, although a greater interest in the matter has been manifested over the past several decades, especially in patients with aneurysmal subarachnoid haemorrhage (aSAH). We present the case of a patient with aSAH and signs of cardiac injury evoked by ECG changes and elevated cardiac enzymes. Furthermore, we reviewed current medical literature by searching the international database PubMed for recent articles on the subject of cardiac biomarkers, ECG and echocardiography changes in the setting of SAH. Our analysis of the selected articles, published between 2012 and 2018, revealed that 22 are patient population studies, 16 are case studies and 6 are reviews of the literature. The most common ECG changes were prolonged QTc and nonspecific ST/T-wave changes. Echocardiography changes included regional wall-motion abnormalities, typically involving the base of the heart (neurogenic stunned myocardium), yet there was also the scenario of Takotsubo cardiomyopathy (stress cardiomyopathy), which affects the apex of the heart. There is a significant statistical association of elevated levels of troponin and NT-proBNP with a bad outcome after SAH, and we should always keep in mind the dramatic scenario of misdiagnosing the cerebral haemorrhage and treating for a coronary syndrome instead. Therefore, the management of aSAH requires a close cooperation between neurosurgeons, intensivists, cardiologists and radiologists in high volume centres.

## INTRODUCTION

Cardiac dysfunction in patients with an intracranial pathology represents a well-known complication and a pressing problem for both neurosurgeons and intensivists treating such a patient. The matter is

## Keywords

subarachnoid haemorrhage – SAH, cardiac dysfunction, electrocardiogram – ECG, cardiac enzymes, troponin, NT-proBNP, echocardiography



Corresponding author:  
**Gabriel Iacob**

Neurosurgery Department,  
Emergency University Hospital,  
Bucharest, Romania

gbrl\_cb@yahoo.com

**Copyright and usage.** This is an Open Access article, distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (<https://creativecommons.org/licenses/by-nc-nd/4.0/>) which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited.

The written permission of the Romanian Society of Neurosurgery must be obtained for commercial re-use or in order to create a derivative work.

ISSN online 2344-4959  
© Romanian Society of  
Neurosurgery



First published  
December 2019 by  
London Academic Publishing  
[www.lapub.co.uk](http://www.lapub.co.uk)

probably best described for cases of subarachnoid hemorrhage (SAH), which account for approximately 10% of all strokes. Most SAHs are caused by ruptured saccular (berry) aneurysms.

This is a devastating clinical event, with a high mortality rate - average case fatality of 51%, as well as substantial neurologic morbidity in survivors (1-7).

The complex interactions between the affected brain and the heart are responsible for unique cardiovascular morbidity and mortality - up to 23% of deaths caused by cardiovascular and pulmonary complications (1)(8)(9). A number of cardiac changes occur in the acute phase of SAH, including ECG changes, structural changes on echocardiography, and acute troponin and NT-proBNP elevations (3)(10-16).

#### CASE PRESENTATION

A 47-year-old man, with a medical history of hypertension, was brought to the emergency department

in Pitesti for repetitive generalized seizures. Upon presentation, he had a Glasgow Coma Scale of 5 (E1, V1, M3), therefore he was sedated and intubated. His wife told the doctors that a few hours earlier he had complained of a severe headache, followed by a reduction in visual acuity for the left eye. Moreover, 2 weeks back, he had presented another severe headache and vomiting. The head CT revealed an interhemispheric hemorrhage and a right-sided fronto-temporo-parietal subdural hematoma. The patient was then transferred to the University Emergency Hospital in Bucharest. Upon admission, he was sedated, with a GCS of 3, anisocoria (mydriasis of the right eye) and left hemiplegia; he was intubated and mechanically ventilated and cardiovascularly stable, with a normal ECG (Fig. 1). An emergency angiography revealed a ruptured aneurysm on the anterior communicating artery, which was embolized. The subdural hematoma was also evacuated.




FIGURE 1. Normal ECG upon admission






FIGURE 2. ST segment depression in the anterolateral territory (V2-V6)



**FIGURE 3.** Atrial flutter, with variable atrio-ventricular block, and antero-lateral ST depression



**FIGURE 4.** T wave flattening in DII, DIII, aVF, V1-V2 and V6

On the third day, the patient was neurologically better – a CGS of 8 (E2, V1, M5), maintaining left hemiplegia, yet still intubated and mechanically ventilated, with an arterial pressure of 105/65 mmHg, tachycardic 108 bpm. His ECG started changing, at first with ST segment depression in V2-V6 (antero-lateral territory), followed by atrial flutter, with variable atrioventricular block, and anterolateral ST depression (Fig. 2,3). Cardiac enzymes were also high – CK 807 U/L, CKMB 105 U/L, troponin I 1,5 ng/ml and NT-proBNP 173 pg/ml, with normal creatinine clearance and electrolytes. On echocardiography, there was a normal left ventricular ejection fraction and no wall-motion anomaly, thus the scenario was interpreted by the cardiologist as neurologically mediated. CK (1262

U/L) and CKMB (203 U/L) reached their peak value 8 hours later, while troponin had a maximum value of 8,26 ng/ml approximately 20 hours later.

A repeated head CT on day 5 revealed a frontal intraparenchymal hemorrhage of 55/14 mm in axial plane and 27 mm cranio-caudal and a bilateral frontal cortico-subcortical ischemic area in the vascularisation territory of the anterior cerebral artery. The vasospasm was confirmed by 2 subsequent angiographies performed on day 5 and 7, when Nimotop (nimodipine) was also locally injected.

CK and CKMB normalized on day 5, while troponin I normalized on day 7. On day 36, the patient was conscious, with a CGS of 13-14 (E 4 V 3-4, M 6) and a residual left hemiparesis, spontaneously

breathing, cardiovascularly stable and a relatively normal ECG (T wave flattening in DII, DIII, aVF, V1-V2 and V6) (Fig. 4).

#### MATERIAL AND METHOD FOR THE LITERATURE REVIEW

We queried the international database PubMed for recent articles using the syntax: subarachnoid [title/abstract], hemorrhage [title/abstract], cardiac [title/abstract], restricted with filters: publication date from 2012/01/01 to 2018/04/01; humans. Afterwards we selected 44 articles tackling the aspects of raised levels of troponin and NT-proBNP and ECG and echocardiography changes in patients with SAH.

#### RESULTS

Our analysis of the selected articles revealed that 22 are patient population studies, 16 are case series and 6 are reviews of the medical literature.

#### ECG abnormalities

Jeong et al., in a study of 122 patients with SAH and no previous heart disease (62% women) [17] aimed to determine the frequency, influencing factors and impact on outcome of cardiac arrhythmias after aSAH. 50% of their population had a clinically significant ECG change, the most common type being nonspecific ST-T changes. A multivariate analysis showed no significant association of various factors (age, sex, Hunt-Hess grade, Fisher grade, hypertension, symptomatic vasospasm and ICU length of stay) with clinically significant arrhythmia. Yet, the presence of ECG changes was independently predictive of death and poor outcome. On the other hand, July et al. (18) managed to demonstrate that ECG abnormalities were significantly associated with total cortisol on day 4 and free cortisol on day 2, while Amin et al. (19) observed a statistically significant association between SAH and QTc prolongation.

Prolonged QT was the most prevalent ECG change in 413 patients from CONSCIOUS-1, a prospective randomized trial of clazosentan for the prevention of angiographic vasospasm (10). In this group of patients, the authors tried to identify ECG changes associated with angiographic vasospasm following SAH and concluded that, on multivariate analysis, QT prolongation and tachycardia are both associated with this complication. Moreover, tachycardia and ST changes were associated with worse clinical outcome.

In another large prospective study - 447 SAH patients, Schmidt et al. (20) confirmed that uncontrolled prolonged heart rate elevation (PEHR) is associated with an increased risk of major cardiopulmonary events: hypertension and hypotension requiring vasoactive therapy, pulmonary edema, myocardial injury evidenced by troponin I elevation and poor outcome. 39% of their patients developed PEHR (heart rate of at least 95 beats/minute, for more than 12 hours), with 68% of them having late-onset PEHR (more than 72 hours after SAH onset), which was correlated with an increased risk of delayed cerebral ischemia from cerebral vasospasm. Multifactorial logistic regression revealed the factors associated with PEHR: nonwhite race, Hunt-Hess score of at least 4 at admission, high admission APACHE-2 score and modified Fisher score. In this study, pre-hospital beta-blocker use was protective against PEHR.

By contrast, in a retrospective review of 254 patients with SAH, Crago et al. found (21) no relationship between the pre-hospital use of ACE inhibitors and/or beta-blockers and the development of pulmonary congestion, elevation in troponin or CKMB, heart rate, ECG changes or echocardiography findings. Moreover, a relationship was described between the use of these drugs and arrhythmias (ventricular or supraventricular) recorded by Holter monitoring, with patients taking beta-blockers.

A study from Japan (22) draws attention on the clinical scenario of comatose patients resuscitated from SAH-associated out-of-hospital cardiac arrest (OHCA) (SAH-OHCA) who often have clinical signs that mimic acute coronary syndrome-associated OHCA (ACS-OHCA) patients. As the management of SAH is totally different from that for ACS, doctors should be able to differentiate between the two as quickly as possible. Yamashina et al. analysed the retrospective data of 1259 consecutive OHCA and included in their study 23 resuscitated comatose ACS-OHCA patients and 20 resuscitated comatose SAH-OHCA patients. ST-T abnormalities on the ECG suggesting myocardial damage were noted in most patients in both groups (95% in the ACS-OHCA and 85% in SAH-OHCA), yet reciprocal ST depression was significantly more often absent in the SAH-OHCA group. Moreover, pulseless electrical activity (PEA) or asystole as the initial cardiac rhythm, female gender, and preserved left ventricular ejection fraction were

significantly more common in the SAH-OHCA group. In their group, initial PEA/asystole and presence of 1 other factor was sufficient to differentiate between SAH and ACS-OHCA patients (100% sensitivity, 91% specificity, 95% accuracy).

Almost all the 16 case reports also point to the possibility of SAH masquerading as an ACS (23-36). One of them presents the scenario of SAH with the pattern of sinus node dysfunction on the ECG (37), while Elsharkawy et al., on a cohort of 20 SAH patients observed that patients with fluctuating ECG changes had a poor outcome compared with patients with fixed abnormalities (38).

### Troponin and NT-proBNP elevation

In a retrospective review of 617 patients with aSAH conducted by Ahmadian et al. (13), 14.1% (87 patients) required a cardiac evaluation: 63% had arrhythmia, 47% suffered a myocardial infarction and 31% developed heart failure. The majority of cases with a myocardial infarction (90.2%) were non-ST elevation MI, while atrial fibrillation was the most common form of tachyarrhythmia described. Among the patients who had a cardiac event at the time of a SAH, those with myocardial infarction, and in particular those with a troponin level greater than 1 mcg/L had a 10 times higher risk of death.

Oras et al. (11), in a single-centre prospective observational study including 126 SAH patients, managed to conclude that both peak levels of troponin (hsTnT in their study) and NT-proBNP are independently associated with cerebral infarction due to delayed cerebral ischemia. hsTnT had its peak level at admission followed by a daily decline; by contrast, NT-proBNP had lowest levels on day 1 after SAH and increased on days 2 to 4. Moreover, age, poor neurological status upon admission, cerebral infarction and peak hsTnT were independently associated with poor late outcome.

The area under the curve (AUC) for the first 4 days was used by Nyberg et al. (39) to quantitatively measure the BNP load during the first critical part of the disease in 138 patients with a SAH. A more severe SAH defined by a higher Fisher and World of Neurosurgical Societies grade, neurological deficits, an aneurysm, infections or higher levels of troponin I at admission had a larger AUC for NT-proBNP. Women, older people and those with poor outcomes also had larger AUC for NT-proBNP.

Terao et al. (40) investigated the relationship between urinary albumin/creatinine ratio (ACR), NT-proBNP level and neurological outcome after SAH in 61 patients. NT-proBNP highest levels were above normal limits in 93% patients, while 85% of them developed microalbuminuria. The study demonstrated on the one hand that the peak value of NT-proBNP was significantly associated with peak troponin value and highest ACR. On the other hand, peak ACR and Hunt-Hess grade were independent predictors of poor neurological outcome.

### Neurogenic myocardial stunning

Prunet et al. (3)(41) evaluated cardiac glucose metabolism and myocardial perfusion and assessed the duration and reversibility of cardiac sympathetic impairment after SAH in 30 hemodynamically stable acute phase SAH patients, by using F-fluorodesoxyglucose positron emission tomography ( $^{18}\text{F}$ -FDGPET),  $^{99\text{m}}\text{Tc}$ -tetrofosmin and  $^{123}\text{I}$ -meta-iodobenzylguanidine ( $^{123}\text{I}$ -mIBG). 83% revealed initial impairment of cardiac glucose metabolism and the defect pattern could not be explained by a single coronary artery distribution, while 90% exhibited initial impairment of cardiac sympathetic innervation. All patients had normal myocardial perfusion and normal left ventricular systolic function. There was a concordance of  $^{123}\text{I}$ -mIBG and  $^{18}\text{F}$ -FDG uptake abnormalities, as well as a common temporal evolution, which suggests the close relationship between myocardial sympathetic function and glucose metabolism; yet neither of them produced left ventricular systolic or diastolic dysfunction in this group of patients (41).

In a group of 300 aSAH patients, Malik et al. (42) tried to determine the risk factors for the occurrence of neurogenic stress cardiomyopathy (NSC), which they defined as having at least one of the following: ECG changes (long Q, T wave inversions), troponin level higher than 0.1 or decreased ejection fraction and wall motion abnormalities on the echocardiogram. After a multivariate analysis, they concluded that higher Hunt-Hess grade on admission, smoking, older age and lack of hypertension were the strongest predictors of NSC.

In a larger group of 715 SAH patients, Bihorac et al. (43), aimed to compare short- and long-term outcomes in patients with different patterns of regional left ventricular dysfunction (RLVD) as a manifestation of stress-induced cardiomyopathy

after SAH. 28% (200 patients) of these patients had an echocardiogram for clinical evidence of cardiac dysfunction, 30% of whom (59 patients) had RLVD. The observation was that the risk of death was significantly higher in patients who need an echocardiogram in the first place, regardless of the presence or absence of RLVD on that echocardiogram.

## CONCLUSION

SAH should probably be the most feared type of stroke event among clinicians. On the one hand, it affects younger adults and individuals in their prime, therefore the individual disability burden and consequential social impact is devastating. On the other hand, SAH is a multisystem disease, and medical complications have been identified as factors that can contribute to worse outcomes, thereby awareness of this fact is warranted.

Cardiac abnormalities are common after SAH, even in non coronary-disease patients. Clinically significant arrhythmias after SAH are associated with a high mortality rate, as well as serious cardiac and neurological comorbidities[17]. These patients should be submitted to a close cardiac monitoring.

Some patients (20-30%) present with acute cardiac enzyme elevation, and an increase in troponin I, which occurs in more severe patients, correlates with poor long-term outcome. Increased levels of troponin, but also NT-proBNP, upon admission are both independently associated with delayed cerebral ischemia (11)(12). Troponin I and NT-proBNP elevation should therefore be early detected and closely monitored and those patients timely managed by a multidisciplinary team of doctors (44).

We should also bear in mind the fact that cardiac alterations associated with SAH include both systolic and diastolic dysfunction of the left ventricle, and that, in order to prevent pulmonary and other organ congestion due to heart dysfunction, it is strongly advised to perform echocardiography on admission of a SAH patient, and to repeatedly monitor this way a patient with SAH and RLVD during the triple H therapy (2)(14)(34)(36).

For comatose OHCA resuscitated patients, initial ED evaluation might be sufficient to differentiate between an ACS or a SAH as the cause of the cardiac arrest, prior to further, time consuming tests (22).

## REFERENCES

1. Okabe et al. - Cardiovascular Protection to Improve Clinical Outcomes After Subarachnoid Hemorrhage: Is There a Proven Role?, *Neurocrit Care* 2013, 18, 271-284
2. Salem R. et al. - Subarachnoid hemorrhage induces an early and reversible cardiac injury associated with catecholamine release: one-week follow-up study, *Critical Care* 2014, 18, 558
3. Prunet et al. - Impairment of cardiac metabolism and sympathetic innervation after aneurysmal subarachnoid hemorrhage: a nuclear medicine imaging study, *Critical Care* 2014, 18, R131
4. Macdonald et al. - Understanding the disease: aneurysmal subarachnoid hemorrhage. *Intensive Care Med* 2014, 40, 1940-1943
5. Inamasu et al. - Effect of insular injury on autonomic functions in patients with ruptured middle cerebral artery aneurysms, *Stroke* 2013, 44, 3550-3552
6. Huang et al. - Comparison of cerebral-cardiac syndrome caused by nonaneurysmal or aneurysmal hemorrhage, *Eur Rev Med Pharmacol Sci*, 2014; 18, 3737-3742
7. Kim et al. - Sudden neurological death masquerading as out-of-hospital sudden cardiac death, *Neurology*, 2016; 87, 1669-1673
8. Krishnamoorthy et al. - Cardiac dysfunction after neurologic injury. What do we know and where are we going? *Chest* 2016; 149(5), 1325-1331
9. Manea et al. - Brain-heart axis – review article. *Journal of Medicine and Life*, 2015; 8, 266-271
10. Ibrahim et al. - Electrocardiographic changes predict angiographic vasospasm after aneurysmal subarachnoid hemorrhage, *Stroke*, 2012; 43, 2102-2107
11. Oras et al. Elevated high-sensitive troponin T on admission is an indicator of poor long-term outcome in patients with subarachnoid haemorrhage: a prospective observational study, *Critical Care*, 2016; 20:11
12. Oras et al. - High-sensitive troponin T and N-Terminal pro B-type Natriuretic Peptide for early detection of stress-induced cardiomyopathy in patients with subarachnoid hemorrhage, *Neurocrit Care*, 2015; 23, 233-242
13. Ahmadian et al. - Cardiac manifestations of subarachnoid hemorrhage, *Heart, Lung and Vessels*, 2013; 5(3), 168-178
14. Kumai et al. - Differences between Takotsubo cardiomyopathy and reverse Takotsubo cardiomyopathy associated with subarachnoid hemorrhage, *IJC Heart & Vasculature*, 2016; 11, 99-103
15. Huang et al. - The 12-lead electrocardiogram in patients with subarachnoid hemorrhage: early risk prognostication, *American Journal of Emergency Medicine*, 2012; 30, 732-736
16. Juntilla et al. - Repolarization abnormalities in patients with subarachnoid and intracerebral hemorrhage: predisposing factors and association with outcome, *Anesth Analg.*, 2013; 116, 190-197
17. Jeong et al. - Clinically significant cardiac arrhythmia in patients with aneurysmal subarachnoid hemorrhage, *J Cerebrovasc Endovasc Neurosurg*, 2012; 14(2), 90-94

18. July et al. - Cortisol dynamics are associated with electrocardiographic abnormalities following the aneurysmal subarachnoid hemorrhage, *J Cardiovasc Dis Res.*, 2012; 3(4), 315-318
19. Amin et al. - QTc interval prolongation and hemorrhagic stroke: any difference between acute spontaneous intracerebral hemorrhage and acute non-traumatic subarachnoid hemorrhage?, *Med Arch*, 2017; 71(3), 193-197
20. Schmidt et al. - Prolonged elevated heart rate is a risk factor for adverse cardiac events and poor outcome after subarachnoid hemorrhage, *Neurocrit Care*, 2014; 20(3), 390-398
21. Crago et al. - Cardiac Abnormalities after aneurysmal subarachnoid hemorrhage: effects of  $\beta$ -blockers and angiotensin-converting enzyme inhibitors, *Am J Crit Care*, 2014; 23(1), 30-39
22. Yamashina et al. - Differentiating between comatose patients resuscitated from acute coronary syndrome-associated and subarachnoid hemorrhage-associated out-of-hospital cardiac arrest, *Journal of Cardiology*, 2015; 65, 508-513
23. Tan et al. - Concurrent subarachnoid haemorrhage and ST elevation myocardial infarction, *JRSM Open*, 2017; 8(2), 1-3
24. Lewandowski P. - Subarachnoid haemorrhage imitating acute coronary syndrome as a cause of out-of-hospital cardiac arrest – case report, *Anaesthesiol Intensive Ther*, 2014; 46(4), 289-292
25. Al-Zaiti et al. - ECG changes during Neurologic injury, *Am J Crit Care*, 2015; 24, 453-454
26. Delelis et al. - Subarachnoid haemorrhage mimicking acute myocardial infarction, *BMJ Case Reports*, 2012
27. Patel et al. - The ischaemic ECG: is it all in the head?, *BMJ Case Rep*, 2013
28. King C. - Listening to the head and not to the heart: subarachnoid haemorrhage associated with severe acute left ventricular failure, *BMJ Case Rep*, 2013
29. Park et al. - Subarachnoid hemorrhage mimicking ST-segment elevation myocardial infarction after return of spontaneous circulation, *Clin Exp Med*, 2015; 2(4), 260-263
30. Chen H. - Angiographic Coronary Spasm in a case of spontaneous subarachnoid hemorrhage mimicking acute myocardial infarction, *Cardiol Resp*, 2013; 4(2), 74-77
31. Pothiwala S. - Spontaneous subarachnoid hemorrhage as a differential diagnosis of pre-hospital cardiac arrest, *Indian J Crit Care Med*, 2012; 16, 216-218
32. Heo et al. - Subarachnoid hemorrhage misdiagnosed as an acute ST elevation myocardial infarction, *Korean Circ J*, 2012; 42(3), 216-219
33. Hatim et al. - A case of subarachnoid hemorrhage revealed by an acute coronary syndrome, *Pan Afr Med J*, 2015; 20, 426
34. Shimada et al. - Takotsubo cardiomyopathy secondary to intracranial hemorrhage. *Int J Emerg Med*, 2014; 7, 33
35. Koklu et al. - Subarachnoid hemorrhage that electrocardiographically mimics acute coronary syndrome: a case report, *Turk Kardiyol Dern Ars*, 2015; 43(8), 730-733
36. Shoukat et al. - Cardiomyopathy with inverted Tako-tsubo pattern in a series of subarachnoid hemorrhage: a series of four cases, *Neurocrit Care*, 2013; 18, 257-260
37. Bisht et al. - Warning leak of intracranial aneurysm masquerading as sinus node dysfunction: a case report, *SAGE Open Med Case Rep*, 2015
38. Elsharkawy et al. - Fluctuating electrocardiographic changes predict poor outcomes after acute subarachnoid hemorrhage, *Ochsner Journal*, 2016; 16, 225-229
39. Nyberg et al. - Predictors of increased cumulative serum levels of the N-terminal prohormone of brain natriuretic peptide 4 days after acute spontaneous subarachnoid hemorrhage, *J Neurosurg*, 2014; 120, 599-604
40. Terao et al. - An observational study of the association between microalbuminuria and increased N-terminal pro-B-type natriuretic peptide in patients with subarachnoid hemorrhage, *Journal of Intensive Care*, 2015; 3, 42
41. Papanikolaou et al. - The role of nuclear cardiac imaging in redefining neurogenic stunned myocardium in subarachnoid hemorrhage: a deeper look into the heart, *Critical Care*, 2014; 18, 490
42. Malik et al. - Neurogenic stress cardiomyopathy after aneurysmal subarachnoid hemorrhage, *World Neurosurg*, 2015; 83(6), 880-885
43. Bihorac et al. - Long-term outcomes for different forms of stress cardiomyopathy after surgical treatment for subarachnoid hemorrhage, *Anesth Analg*, 2016; 122(5), 1594-1602
44. Mavridis et al. - Troponin elevation in subarachnoid hemorrhage, *Journal of Acute Disease*, 2015; 4(1), 7-11.